Rapid Discovery of Antagonistic Human/Cyno CD200R1Llama VHH Nanobodies Using Single B Cell Technology

Nanobodies are a growing modality in antibody therapeutics, with FDA-approved treatments driving demand for VHH discovery. Their small size and typically longer CDR3 enables targeting challenging epitopes in solid tumors, overcoming limitations of larger antibodies. Here we used single B cell antibody discovery to rapidly identify a diverse set of potent, high affinity, neutralizing VHH from immunized llamas against CD200R1, an emerging therapeutic immune checkpoint target.

Curia’s optimized high-throughput single B cell-based VHH discovery workflow, which leverages Bruker’s Beacon® Optofluidic system and Curia’s rapid gene-to-protein (GTP) productions, significantly accelerates identification of high quality, high affinity VHH leads.

(Click on poster image for access to full document)